HMGA2 promotes resistance against paclitaxel by targeting the p53 signaling pathway in colorectal cancer cells
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.High-mobility group A2 (HMGA2) promotes colorectal cancer aggressiveness and paclitaxel resistance. Targeting HMGA2 and p53 signaling may offer new therapeutic strategies for colorectal cancer treatment.
Area Of Science
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background
- Colorectal cancer (CRC) is a leading cause of cancer mortality globally, characterized by metastasis and drug resistance.
- High-mobility group A2 (HMGA2) is overexpressed in CRC, correlating with tumor aggressiveness and promoting drug resistance, but its mechanism remains unclear.
Purpose Of The Study
- To elucidate the molecular mechanism of HMGA2 in colorectal cancer progression and paclitaxel (PTX) resistance.
- To investigate the role of HMGA2 in regulating colorectal cancer cell response to PTX and its interaction with p53 signaling.
Main Methods
- HMGA2 expression analysis in colorectal cancer tissues.
- In vitro studies involving HMGA2 knockdown and overexpression in colorectal cancer cells.
- Assessment of cell viability, migration, reactive oxygen species (ROS) levels, and mitochondrial potential post-PTX treatment.
- RNA sequencing to identify regulatory pathways, followed by combination therapy with p53 inhibitors.
Main Results
- HMGA2 is overexpressed in colorectal cancer and its knockdown inhibits cell growth and migration.
- HMGA2 modulates colorectal cancer cell sensitivity to PTX; knockdown increases cell death, while overexpression decreases it.
- HMGA2 influences ROS levels and mitochondrial potential in response to PTX, and regulates p53 signaling pathways.
Conclusions
- HMGA2 activates p53 signaling to regulate colorectal cancer cell death following PTX treatment.
- HMGA2 contributes to paclitaxel resistance in colorectal cancer.
- Targeting HMGA2 and p53 signaling presents a potential therapeutic strategy for colorectal cancer.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...